MSB Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Mesoblast Insider Trading History Chart

This chart shows the insider buying and selling history at Mesoblast by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Mesoblast Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for MSB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
The "NEW" Oil and Gas Crisis: Lack Of Lithium
We are in a global lithium crisis that's going to get far worse. Just like OPEC and Russia control the price and supply of oil and gas, China has the U.S. in a chokehold when it comes to lithium.
Click here to see how the prices may explode

Mesoblast Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/14/2022Philip FacchinaInsiderIssued200,000A$1.31A$262,000.00
6/24/2020Silviu ItescuInsiderIssued1,885,334A$3.47A$6,542,108.98
12/3/2019William (Bill) BurnsInsiderBuy32,670A$1.83A$59,786.10
See Full Table

SEC Filings (Institutional Ownership Changes) for Mesoblast (ASX:MSB)

Mesoblast logo
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Read More on Mesoblast

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


10,191,278 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Mesoblast?

Mesoblast's top insider shareholders include:
  1. Philip Facchina (Insider)
Learn More about top insider investors at Mesoblast.